Protagonist TherapeuticsPTGX
PTGX
About: Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Employees: 126
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
225% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 24
35% more capital invested
Capital invested by funds: $2.07B [Q2] → $2.8B (+$728M) [Q3]
27% more funds holding
Funds holding: 187 [Q2] → 238 (+51) [Q3]
19% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 64
3.69% more ownership
Funds ownership: 101.94% [Q2] → 105.64% (+3.69%) [Q3]
45% less call options, than puts
Call options by funds: $2.83M | Put options by funds: $5.18M
50% less funds holding in top 10
Funds holding in top 10: 8 [Q2] → 4 (-4) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$50
30%
upside
Avg. target
$56
45%
upside
High target
$62
61%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Brian Cheng 24% 1-year accuracy 5 / 21 met price target | 38%upside $53 | Overweight Maintained | 4 Feb 2025 |
HC Wainwright & Co. Douglas Tsao 32% 1-year accuracy 56 / 176 met price target | 30%upside $50 | Buy Reiterated | 10 Dec 2024 |
BMO Capital Etzer Darout 22% 1-year accuracy 9 / 41 met price target | 61%upside $62 | Outperform Initiated | 6 Dec 2024 |
Wedbush Yun Zhong 0% 1-year accuracy 0 / 4 met price target | 51%upside $58 | Outperform Initiated | 5 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
3 weeks ago
Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck
Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025. The global Polycythemia vera market size is expected to grow to $2.03 billion by 2032.
Neutral
Accesswire
4 weeks ago
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter.
Neutral
Accesswire
1 month ago
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Neutral
Accesswire
2 months ago
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Neutral
Accesswire
2 months ago
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274 The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1698744&tp_key=f6482f31c0 A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
Positive
Zacks Investment Research
2 months ago
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Zacks Investment Research
2 months ago
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.58 per share a year ago.
Neutral
Accesswire
2 months ago
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024 Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in Q1 2025 Top line results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in Q1 2025 Development candidate nomination for oral IL-17 peptide antagonist expected in Q4 2024 Cash, cash equivalents and marketable securities of $583.3 million as of September 30, 2024, anticipated to provide cash runway through end of 2027 NEWARK, CA / ACCESSWIRE / November 7, 2024 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. "Protagonist is approaching multiple transformational events with the pending readouts of JNJ-2113 in Phase 3 psoriasis studies this year, Phase 2b ulcerative colitis study in Q1 2025, and rusfertide Phase 3 study in polycythemia vera in Q1 2025," said Dinesh V.
Neutral
Accesswire
3 months ago
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera will be the focus of a poster presentation at the 66th Annual American Society of Hematology (ASH) Annual Meeting being held in San Diego from December 7-10, 2024. ASH Presentation Details: Presenting author: Aaron Gerds, MD (Cleveland Clinic) Publication Number: 4559 Title: Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV) Session Name: 634.
Positive
Zacks Investment Research
3 months ago
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Charts implemented using Lightweight Charts™